ARS Pharmaceuticals, Inc.

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.35 ^USD	+3.21%		-1.42%	+52.37%

Apr. 18	ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	MT
Apr. 18	ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	MT

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index

March 17, 2024

Latest news about ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	Apr. 10	MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	Apr. 03	MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	Apr. 03	DJ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	Apr. 03	CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	Mar. 05	MT
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study	Feb. 26	CI
ARS Pharmaceuticals' Repeat Dose Study Shows Epinephrine Nasal Spray as Good as Injection	Feb. 20	MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	Feb. 20	MT
ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA?s Complete Response Letter	Feb. 20	CI
Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	Feb. 06	MT
Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	Nov. 13	MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ARS Pharmaceuticals Says US Food and Drug Administration Schedules Type A Meeting on Allergy Spray for End of October	23-10-06	MT
ARS Pharmaceuticals to Meet With FDA on Neffy Rejection	23-10-06	DJ
Ars Pharmaceuticals, Inc. Announces Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology	23-10-03	CI
Ars Pharmaceuticals Insider Bought Shares Worth $319,954, According to a Recent SEC Filing	23-10-02	MT
Sector Update: Health Care Stocks Declining Late Thursday Afternoon	23-09-21	MT
Sector Update: Health Care	23-09-21	MT
ARS Pharmaceuticals Likely to Get Approval for Epinephrine Nasal Spray in H2 2024, Wedbush Says	23-09-21	MT
North American Morning Briefing : The Post-Fed -2-	23-09-21	DJ

Chart ARS Pharmaceuticals, Inc.

Duration

Period

More charts

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ARS Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.35 USD

Average target price

19 USD

Spread / Average Target

+127.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARS PHARMACEUTICALS, INC.	+52.37%	809M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research